Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · All participants received 18 weeks of chemotherapy with paclitaxel 80 mg/m 2 IV once weekly and non-pegylated liposomal doxorubicin 20 mg/m 2 IV once weekly. Patients with TNBC received simultaneous bevacizumab 15 mg/kg IV once every 3 weeks.
14 Ιουν 2019 · The increased activity rate of this signalling pathway was observed following neoadjuvant chemotherapy and this suggests that recurrent patients with TNBC and JAK2 amplification could benefit from the blockade of this signalling pathway 25.
Identification of biomarkers to optimize treatment strategies for early-stage triple-negative breast cancer (TNBC) is crucial. This study presents the development and validation of TNBC-DX, a novel test aimed at predicting both short- and long-term outcomes in early-stage TNBC.
The addition of immunotherapy to chemotherapy for the treatment of patients with early stage TNBC in the (neo) adjuvant setting per the pivotal KEYNOTE 522 significantly improved pCR rates.
18 Ιαν 2024 · In this study, we examined blood cytokine profiles of TNBC patients throughout treatments (pre-treatment, during chemotherapy, pre-surgery, and 1 year after the surgery in a total of 294...
Abstract. Triple-negative breast cancer (TNBC) is associated with an increased risk of early recurrence and distant metastasis, as well as the development of therapeutic resistance and poor prognosis. TNBC is characterized by a wide range of genetic, immunophenotypic, morphological, and clinical features.
30 Μαΐ 2023 · Potential opportunities to “right-size” systemic therapy in operable triple negative breast cancer (TNBC). In the future, patients with germline BRCA (gBRCA) or PALB2 mutations may be candidates for a neoadjuvant poly (ADP-ribose) polymerase inhibitor (PARPi) rather than cytotoxic chemotherapy.
